COMMUNIQUÉS West-GlobeNewswire

Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024
20/03/2024
MOUNTAIN VIEW, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
20/03/2024
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist - - Cash [...]
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
20/03/2024
Trem-cel and VCAR33 ALLO clinical trial data expected in the second half of 2024 VCAR33 ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of [...]
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
20/03/2024
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million of cash, cash equivalents and marketable securities as of [...]
Spectral AI Secures Access to $12.5 Million of New Equity Capital
20/03/2024
Issuance of Convertible Instrument Balances Certainty, Timing, and Execution Capital Supports Strategic Imperatives and Commercialization Initiatives DALLAS, March 20, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq [...]
Nika Pharmaceuticals, Inc. (NKPH) Merges With Nika Biotechnology, Inc.
20/03/2024
HENDERSON, Nev., March 20, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH ) announces its merger with Nika BioTechnology, Inc., effective as of March 1, 2024. On August 1, 2022, Nika Pharmaceuticals [...]
ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option
20/03/2024
EINDHOVEN, the Netherlands, March 20, 2024 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE [...]
ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option
20/03/2024
EINDHOVEN, the Netherlands, March 20, 2024 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE [...]
ONWARD® Medical Lance une Augmentation de Capital par le Biais d'une Procédure de Construction Accélérée d'un Livre d'Ordres et le Biais d'une Offre au Public en France d'un Montant Indicatif de 15 millions d'euros avec l’Option de Lever j
20/03/2024
EINDHOVEN, the Netherlands, 20 mars 2024 (GLOBE NEWSWIRE) -- NE PAS DISTRIBUER OU DIFFUSER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS, AU CANADA, EN AUSTRALIE OU AU JAPON OU DANS TOUTE AUTRE JURIDICTION DANS LAQUELLE [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of March 13, 2024
20/03/2024
Disclosure of Share Capital and Voting Rights Outstanding as of March 13, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 13 mars 2024
20/03/2024
Nombre total de droits de vote et d’actions composant le capital social au 13 mars 2024 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Charenton- [...]
PHAXIAM Announces 2023 Full-Year Results and Provides Business Update
20/03/2024
Conference call and webcast (English) on Thursday, March 21, 2024 at 9:30am ET / 2:30pm CET Ongoing clinical efforts boding well to create a global phage-therapy leader in high-value indications First clinical results [...]
PHAXIAM Therapeutics publie ses résultats annuels 2023 et fait le point sur ses activités
20/03/2024
Webinaire en français le jeudi 21 mars 2024 à 11h00 CET : inscrivez-vous ici Stratégie clinique en phase avec l’objectif de créer un leader mondial de la phagothérapie dans des indications à forte valeur ajoutée [...]
Zealand Pharma's Annual General Meeting 2024
20/03/2024
Company announcement – No. 17 / 2024 Zealand Pharma's Annual General Meeting 2024 Copenhagen, March 20, 2024 - Today, Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR no. 20 04 50 78), held its Annual General Meeting [...]
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
20/03/2024
FORT WORTH, March 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing [...]
DAS Health Expands Presence with New Chicago Office Location
20/03/2024
Chicago, March 20, 2024 (GLOBE NEWSWIRE) -- DAS Health, a nationally recognized leader in providing comprehensive health IT and management solutions exclusively for healthcare clients, is thrilled to announce the grand [...]
SEQUANA MEDICAL LAUNCHES EQUITY PLACEMENT AND PROVIDES TRADING UPDATE
20/03/2024
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW [...]
Orion Corporation: Organising meeting of the Board of Directors
20/03/2024
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 20 MARCH 2024 at 17.00 EET Orion Corporation: Organising meeting of the Board of Directors In its organising [...]
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed
20/03/2024
Seek approval from the FDA for the modification of the Gloperba ® label to include its ability to utilize dosing flexibility of liquid formulation to address unmet medical needs and provide specific dosing guidance to [...]

Pages